<DOC>
	<DOCNO>NCT01747564</DOCNO>
	<brief_summary>The purpose study evaluate safety absorption , distribution elimination mirabegron oral administration Chinese subject .</brief_summary>
	<brief_title>A Study Evaluate Absorption , Distribution Elimination Mirabegron After Oral Administration Non-elderly Healthy Chinese Subjects</brief_title>
	<detailed_description>This study open-label study . The subject receive single administration mirabegron fast condition . After non-dosing period , subject receive mirabegron 8 day .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Body weight : ( male ) 50.0kg less 80.0kg ( female ) 40.0kg less 70.0kg Body Mass Index : 17.6 less 26.4 kg/m Chinese subject Healthy judge investigator subinvestigator Received investigational drug within 120 day screen assessment Donated 400 mL whole blood within 90 day , 200 mL whole blood within 30 day , blood component within 14 day screen assessment Received medication within 7 day hospital admission A deviation assessment criterion physical examination laboratory test screen upon admission History drug allergy With renal , hepatic , gastrointestinal , heart , cerebrovascular respiratory disease Received mirabegron beforehand Glaucoma patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Phase 1</keyword>
	<keyword>YM178</keyword>
</DOC>